Defining differential genetic signatures in cxcr4- and the ccr5-utilizing hiv-1 co-linear sequences

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Aiamkitsumrit, Benjamas ^a   Dampier, Will ^a   Martin Garcia, Julio ^a   Nonnemacher, Michael R ^a   Pirrone, Vanessa ^a   Ivanova, Tatyana ^a   Zhong, Wen ^a   Kilareski, Evelyn ^a   Aldigun, Hazeez ^a   Frantz, Brian ^a   Rimbey, Matthew ^a   Wojno, Adam ^a   Passic, Shendra ^a   Williams, Jean W ^a   Shah, Sonia ^a   Blakey, Brandon ^a   Parikh, Nirzari ^a   Jacobson, Jeffrey M ^a   Moldover, Brian ^a,b   Wigdahl, Brian ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b B Tech Consulting Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; TRANSACTIVATOR PROTEIN; VPR PROTEIN; CCR5 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ARTICLE; BLOOD ANALYSIS; CD4 LYMPHOCYTE PERCENTAGE; CD4+ T LYMPHOCYTE; CELL LINEAGE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; GENE SEQUENCE; GENE SIGNATURE; GENE STRUCTURE; GENETIC DATABASE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONG TERMINAL REPEAT; MACROPHAGE; MONOCYTE; NONHUMAN; PHYLOGENY; PROTEIN DOMAIN; VIRUS ENTRY; VIRUS REPLICATION; VIRUS TRANSMISSION; ALGORITHM; CELL LINE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; VIRUS GENE;

ALGORITHMS; CELL LINE; GENES, VIRAL; HIV-1; HUMANS; RECEPTORS, CCR5; RECEPTORS, CXCR4;

EID: 84907495406     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107389     Document Type: Article

References (116)

1. Sattentau QJ, Moore JP (1991) Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 174: 407-415
2. Salzwedel K, Smith ED, Dey B, Berger EA (2000) Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. J Virol 74: 326-333
3. Sattentau QJ, Moore JP, Vignaux F, Traincard F, Poignard P (1993) Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J Virol 67: 7383-7393
4. Eckert DM, Kim PS (2001) Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70: 777-810
5. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, et al. (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature 381: 661-666
6. Moore JP, Kitchen SG, Pugach P, Zack JA (2004) The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 20: 111-126
7. Dimonte S, Babakir-Mina M, Mercurio F, Di Pinto D, Ceccherini-Silberstein F, et al. (2012) Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120(V3) signatures in the regulation of co-receptor usage. Virus Res 168: 73-83
8. Rossi F, Querido B, Nimmagadda M, Cocklin S, Navas-Martin S, et al. (2008) The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors. Retrovirology 5: 89
9. Masciotra S, Owen SM, Rudolph D, Yang C, Wang B, et al. (2002) Temporal relationship between V1V2 variation, macrophage replication, and coreceptor adaptation during HIV-1 disease progression. AIDS 16: 1887-1898
10. Carrillo A, Ratner L (1996) Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants. J Virol 70: 1301-1309
11. Monno L, Saracino A, Scudeller L, Punzi G, Brindicci G, et al. (2011) Impact of mutations outside the V3 region on coreceptor tropism phenotypically assessed in patients infected with HIV-1 subtype B. Antimicrob Agents Chemother 55: 5078-5084
12. Sharon M, Kessler N, Levy R, Zolla-Pazner S, Gorlach M, et al. (2003) Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure 11: 225-236
13. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, et al. (2007) Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 51: 566-575
14. Trouplin V, Salvatori F, Cappello F, Obry V, Brelot A, et al. (2001) Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J Virol 75: 251-259
15. Sierra S, Kaiser R, Thielen A, Lengauer T (2007) Genotypic coreceptor analysis. Eur J Med Res 12: 453-462
16. Verhofstede C, Brudney D, Reynaerts J, Vaira D, Fransen K, et al. (2011) Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA. HIV Med 12: 544-552
17. Jensen MA, van 't Wout AB (2003) Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev 5: 104-112
18. Prosperi MC, Fanti I, Ulivi G, Micarelli A, De Luca A, et al. (2009) Robust supervised and unsupervised statistical learning for HIV type 1 coreceptor usage analysis. AIDS Res Hum Retroviruses 25: 305-314
19. Sing T, Low AJ, Beerenwinkel N, Sander O, Cheung PK, et al. (2007) Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 12: 1097-1106
20. Soulie C, Derache A, Aime C, Marcelin AG, Carcelain G, et al. (2008) Comparison of two genotypic algorithms to determine HIV-1 tropism. HIV Med 9: 1-5
21. Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D, et al. (2003) Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 77: 13376-13388
22. Fassati A, Goff SP (2001) Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J Virol 75: 3626-3635
23. Meltzer MS, Skillman DR, Hoover DL, Hanson BD, Turpin JA, et al. (1990) Macrophages and the human immunodeficiency virus. Immunol Today 11: 217-223
24. Duncan CJ, Sattentau QJ (2011) Viral determinants of HIV-1 macrophage tropism. Viruses 3: 2255-2279
25. Mefford ME, Gorry PR, Kunstman K, Wolinsky SM, Gabuzda D (2008) Bioinformatic prediction programs underestimate the frequency of CXCR4 usage by R5X4 HIV type 1 in brain and other tissues. AIDS Res Hum Retroviruses 24: 1215-1220
26. Schweighardt B, Roy AM, Meiklejohn DA, Grace EJ 2nd, Moretto WJ, Heymann JJ, Nixon DF (2004) R5 human immunodeficiency virus type 1 (HIV-1) replicates more efficiently in primary CD4+ T-cell cultures than X4 HIV-1. J Virol 78(17): 9164-9173
27. Ochsenbauer C, Edmonds TG, Ding H, Keele BF, Decker J, et al. (2012) Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol 86: 2715-2728
28. Wilen CB, Parrish NF, Pfaff JM, Decker JM, Henning EA, et al. (2011) Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol 85: 8514-8527
29. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: 7552-7557
30. Sawaya BE, Khalili K, Gordon J, Taube R, Amini S (2000) Cooperative interaction between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome. J Biol Chem 275: 35209-35214
31. Kilareski EM, Shah S, Nonnemacher MR, Wigdahl B (2009) Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage. Retrovirology 6: 118
32. Bukrinsky M, Adzhubei A (1999) Viral protein R of HIV-1. Rev Med Virol 9: 39-49
33. Azad AA (2000) Could Nef and Vpr proteins contribute to disease progression by promoting depletion of bystander cells and prolonged survival of HIVinfected cells? Biochem Biophys Res Commun 267: 677-685
34. Emerman M, Malim MH (1998) HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 280: 1880-1884
35. Emerman M (1996) HIV-1, Vpr and the cell cycle. Curr Biol 6: 1096-1103
36. Tungaturthi PK, Sawaya BE, Ayyavoo V, Murali R, Srinivasan A (2004) HIV- 1 Vpr: genetic diversity and functional features from the perspective of structure. DNA Cell Biol 23: 207-222
37. Srinivasan A, Ayyavoo V, Mahalingam S, Kannan A, Boyd A, et al. (2008) A comprehensive analysis of the naturally occurring polymorphisms in HIV-1 Vpr: potential impact on CTL epitopes. Virol J 5: 99
38. Bano AS, Gupta N, Sharma Y, Sood V, Banerjea AC (2007) HIV-1 VprB and C RNA cleavage by potent 10-23 DNAzymes that also cause reversal of G2 cell cycle arrest mediated by Vpr genes. Oligonucleotides 17: 465-472
39. Bano AS, Gupta N, Sood V, Banerjea AC (2007) Vpr from HIV-1 subtypes B and C exhibit significant differences in their ability to transactivate LTRmediated gene expression and also in their ability to promote apoptotic DNA ladder formation. AIDS 21: 1832-1834
40. Bano AS, Sood V, Neogi U, Goel N, Kuttiat VS, et al. (2009) Genetic and functional characterization of human immunodeficiency virus type 1 VprC variants from north India: presence of unique recombinants with mosaic genomes from B, C and D subtypes within the open reading frame of Vpr. J Gen Virol 90: 2768-2776
41. Mologni D, Citterio P, Menzaghi B, Zanone Poma B, Riva C, et al. (2006) Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients. AIDS 20: 567-574
42. Yedavalli VR, Ahmad N (2001) Low conservation of functional domains of HIV type 1 vif and vpr genes in infected mothers correlates with lack of vertical transmission. AIDS Res Hum Retroviruses 17: 911-923
43. Garcia-Blanco MA, Cullen BR (1991) Molecular basis of latency in pathogenic human viruses. Science 254: 815-820
44. Cullen BR (1991) Regulation of HIV-1 gene expression. FASEB J 5: 2361-2368
45. Mancebo HS, Lee G, Flygare J, Tomassini J, Luu P, et al. (1997) P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev 11: 2633-2644
46. Conaway JW, Shilatifard A, Dvir A, Conaway RC (2000) Control of elongation by RNA polymerase II. Trends Biochem Sci 25: 375-380
47. Zhu Y, Pe'ery T, Peng J, Ramanathan Y, Marshall N, et al. (1997) Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev 11: 2622-2632
48. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA (1998) A novel CDK9- associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92: 451-462
49. Eugenin EA, King JE, Nath A, Calderon TM, Zukin RS, et al. (2007) HIV-tat induces formation of an LRP-PSD-95- NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes. Proc Natl Acad Sci U S A 104: 3438-3443
50. Tyor W, Fritz-French C, Nath A (2013) Effect of HIV clade differences on the onset and severity of HIV-associated neurocognitive disorders. J Neurovirol 19:515-522
51. Rao VR, Neogi U, Talboom JS, Padilla L, Rahman M, et al. (2013) Clade C HIV-1 isolates circulating in Southern Africa exhibit a greater frequency of dicysteine motif-containing Tat variants than those in Southeast Asia and cause increased neurovirulence. Retrovirology 10: 61
52. Butto S, Fiorelli V, Tripiciano A, Ruiz-Alvarez MJ, Scoglio A, et al. (2003) Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans. J Infect Dis 188: 1171-1180
53. Neogi U, Gupta S, Sahoo PN, Shet A, Rao SD, et al. (2012) Genetic characterization of HIV-1 Tat exon 1 from a southern Indian clinical cohort: identification of unique epidemiological signature residues. AIDS Res Hum Retroviruses 28:1152-1156
54. Hutto C, Zhou Y, He J, Geffin R, Hill M, et al. (1996) Longitudinal studies of viral sequence, viral phenotype, and immunologic parameters of human immunodeficiency virus type 1 infection in perinatally infected twins with discordant disease courses. J Virol 70: 3589-3598
55. Cowley D, Gray LR, Wesselingh SL, Gorry PR, Churchill MJ (2011) Genetic and functional heterogeneity of CNS-derived tat alleles from patients with HIV-associated dementia. J Neurovirol 17: 70-81
56. King JE, Eugenin EA, Buckner CM, Berman JW (2006) HIV tat and neurotoxicity. Microbes Infect 8: 1347-1357
57. Mayne M, Bratanich AC, Chen P, Rana F, Nath A, et al. (1998) HIV-1 tat molecular diversity and induction of TNF-alpha: implications for HIV-induced neurological disease. Neuroimmunomodulation 5: 184-192
58. Fields BN, Knipe DM, Howley PM (2007) Fields' virology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 5th edition: 2664
59. Nonnemacher MR, Irish BP, Liu Y, Mauger D, Wigdahl B (2004) Specific sequence configurations of HIV-1 LTR G/C box array result in altered recruitment of Sp isoforms and correlate with disease progression. J Neuroimmunol 157: 39-47
60. Hogan TH, Stauff DL, Krebs FC, Gartner S, Quiterio SJ, et al. (2003) Structural and functional evolution of human immunodeficiency virus type 1 long terminal repeat CCAAT/enhancer binding protein sites and their use as molecular markers for central nervous system disease progression. J Neurovirol 9: 55-68
61. Ross HL, Gartner S, McArthur JC, Corboy JR, McAllister JJ, et al. (2001) HIV-1 LTR C/EBP binding site sequence configurations preferentially encountered in brain lead to enhanced C/EBP factor binding and increased LTR-specific activity. J Neurovirol 7: 235-249
62. Burdo TH, Gartner S, Mauger D, Wigdahl B (2004) Region-specific distribution of human immunodeficiency virus type 1 long terminal repeats containing specific configurations of CCAAT/enhancer-binding protein site II in brains derived from demented and nondemented patients. J Neurovirol 10 Suppl 1: 7-14
63. Henderson AJ, Connor RI, Calame KL (1996) C/EBP activators are required for HIV-1 replication and proviral induction in monocytic cell lines. Immunity 5: 91-101
64. Henderson AJ, Calame KL (1997) CCAAT/enhancer binding protein (C/ EBP) sites are required for HIV-1 replication in primary macrophages but not CD4(+) T cells. Proc Natl Acad Sci U S A 94: 8714-8719
65. Fu YX (2001) Estimating mutation rate and generation time from longitudinal samples of DNA sequences. Mol Biol Evol 18: 620-626
66. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, et al. (2004) Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303: 2019-2022
67. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, et al. (2005) Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 79: 6528-6531
68. Liu Y, Curlin ME, Diem K, Zhao H, Ghosh AK, et al. (2008) Env length and N-linked glycosylation following transmission of human immunodeficiency virus Type 1 subtype B viruses. Virology 374: 229-233
69. Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Hraber PT, et al. (2011) Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog 7: e1002209
70. Parker ZF, Iyer SS, Wilen CB, Parrish NF, Chikere KC, et al. (2013) Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J Virol 87: 2401-2411
71. Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, et al. (2013) Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A 110: 6626-6633
72. Schuitemaker H, Fouchier RA, Broersen S, Groenink M, Koot M, et al. (1995) Envelope V2 configuration and HIV-1 phenotype: clarification. Science 268: 115
73. Poss M, Martin HL, Kreiss JK, Granville L, Chohan B, et al. (1995) Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1. J Virol 69: 8118-8122
74. Doranz BJ, Orsini MJ, Turner JD, Hoffman TL, Berson JF, et al. (1999) Identification of CXCR4 domains that support coreceptor and chemokine receptor functions. J Virol 73: 2752-2761
75. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, et al. (1992) Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 66: 1354-1360
76. Nora T, Bouchonnet F, Labrosse B, Charpentier C, Mammano F, et al. (2008) Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses. Retrovirology 5: 23
77. Joos B, Trkola A, Fischer M, Kuster H, Rusert P, et al. (2005) Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions. J Virol 79: 9026-9037
78. Sagar M, Kirkegaard E, Lavreys L, Overbaugh J (2006) Diversity in HIV-1 envelope V1-V3 sequences early in infection reflects sequence diversity throughout the HIV-1 genome but does not predict the extent of sequence diversity during chronic infection. AIDS Res Hum Retroviruses 22: 430-437
79. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR (1997) Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 185: 621-628
80. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J (1992) Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 66: 6777-6780
81. Pillai S, Good B, Richman D, Corbeil J (2003) A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 19: 145-149
82. Li L, Aiamkitsumrit B, Pirrone V, Nonnemacher MR, Wojno A, et al. (2011) Development of co-selected single nucleotide polymorphisms in the viral promoter precedes the onset of human immunodeficiency virus type 1- associated neurocognitive impairment. J Neurovirol 17: 92-109
83. Kogan M, Rappaport J (2011) HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention. Retrovirology 8: 25
84. Ferrucci A, Nonnemacher MR, Wigdahl B (2011) Human immunodeficiency virus viral protein R as an extracellular protein in neuropathogenesis. Adv Virus Res 81: 165-199
85. Li L, Dahiya S, Kortagere S, Aiamkitsumrit B, Cunningham D, et al. (2012) Impact of Tat genetic variation on HIV-1 disease. Adv Virol 2012: 123605
86. Los Alamos National Laboratory. http://www.hiv.lanl.gov. Accessed 2014 August 27
87. Hogan TH, Krebs FC, Wigdahl B (2002) Regulation of human immunodeficiency virus type 1 gene expression and pathogenesis by CCAAT/enhancer binding proteins in cells of the monocyte/macrophage lineage. J Neurovirol 8 Suppl 2: 21-26
88. Henderson AJ, Zou X, Calame KL (1995) C/EBP proteins activate transcription from the human immunodeficiency virus type 1 long terminal repeat in macrophages/monocytes. J Virol 69: 5337-5344
89. Gallo RC, Sarngadharan MG, Popovic M, Shaw GM, Hahn B, et al. (1986) HTLV-III and the etiology of AIDS. Prog Allergy 37: 1-45
90. Hahn BH, Shaw GM, Taylor ME, Redfield RR, Markham PD, et al. (1986) Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science 232: 1548-1553
91. Markham RB, Schwartz DH, Templeton A, Margolick JB, Farzadegan H, et al. (1996) Selective transmission of human immunodeficiency virus type 1 variants to SCID mice reconstituted with human peripheral blood monoclonal cells. J Virol 70: 6947-6954
92. Markham RB, Wang WC, Weisstein AE, Wang Z, Munoz A, et al. (1998) Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Proc Natl Acad Sci U S A 95: 12568-12573
93. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, et al. (1996) CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272: 1955-1958
94. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, et al. (1996) The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2: 1240-1243
95. Kitayama H, Miura Y, Ando Y, Hoshino S, Ishizaka Y, et al. (2008) Human immunodeficiency virus type 1 Vpr inhibits axonal outgrowth through induction of mitochondrial dysfunction. J Virol 82: 2528-2542
96. Zhou Y, Ratner L (2001) A novel inducible expression system to study transdominant mutants of HIV-1 Vpr. Virology 287: 133-142
97. Macian F, Rao A (1999) Reciprocal modulatory interaction between human immunodeficiency virus type 1 Tat and transcription factor NFAT1. Mol Cell Biol 19: 3645-3653
98. Ambrosino C, Ruocco MR, Chen X, Mallardo M, Baudi F, et al. (1997) HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors. J Biol Chem 272: 14883-14892
99. Mbonye U, Karn J (2011) Control of HIV latency by epigenetic and nonepigenetic mechanisms. Curr HIV Res 9: 554-567
100. Kalantari P, Narayan V, Natarajan SK, Muralidhar K, Gandhi UH, et al. (2008) Thioredoxin reductase-1 negatively regulates HIV-1 transactivating protein Tat-dependent transcription in human macrophages. J Biol Chem 283: 33183-33190
101. Schmidtmayerova H, Alfano M, Nuovo G, Bukrinsky M (1998) Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4-mediated pathway: replication is restricted at a postentry level. J Virol 72: 4633-4642
102. Holzmeister J, Ludewig B, Pauli G, Simon D (1993) Sequence specific binding of the transcription factor c-Ets1 to the human immunodeficiency virus type I long terminal repeat. Biochem Biophys Res Commun 197: 1229-1233
103. Roebuck KA, Saifuddin M (1999) Regulation of HIV-1 transcription. Gene Expr 8: 67-84
104. Canonne-Hergaux F, Aunis D, Schaeffer E (1995) Interactions of the transcription factor AP-1 with the long terminal repeat of different human immunodeficiency virus type 1 strains in Jurkat, glial, and neuronal cells. J Virol 69: 6634-6642
105. Lu Y, Stenzel M, Sodroski JG, Haseltine WA (1989) Effects of long terminal repeat mutations on human immunodeficiency virus type 1 replication. J Virol 63: 4115-4119
106. Cooney AJ, Tsai SY, O'Malley BW, Tsai MJ (1991) Chicken ovalbumin upstream promoter transcription factor binds to a negative regulatory region in the human immunodeficiency virus type 1 long terminal repeat. J Virol 65: 2853-2860
107. Bruland T, Lavik LA, Dai HY, Dalen A (2003) A glucocorticoid response element in the LTR U3 region of Friend murine leukaemia virus variant FIS-2 enhances virus production in vitro and is a major determinant for sex differences in susceptibility to FIS-2 infection in vivo. J Gen Virol 84: 907-916
108. McAllister JJ, Phillips D, Millhouse S, Conner J, Hogan T, et al. (2000) Analysis of the HIV-1 LTR NF-kappaB-proximal Sp site III: evidence for cell typespecific gene regulation and viral replication. Virology 274: 262-277
109. Tamura K, Peterson N, Stecher G, Nei M, Kumar S (April 2011) MEGA. 5.05 ed. Molecular evolutionary genetics analysis using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods. Molecular Biology and Evolution 28: 2731-2739. Available: http://www.megasoftware.net. Accessed 2014 August 27
110. Jones DT, Taylor WR, Thornton JM (1992) The rapid generation of mutation data matrices from protein sequences. Comput Appl Biosci 8: 275-282
111. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, et al. (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28: 2731-2739
112. S. Nei M, Kumar S (2000) Molecular evolution and phylogenetics. New York: Oxford University Press. 333 p
113. Max Planck Institut fü r Informatik (2011) Geno2Pheno. Available: http:// www.mpi-inf.mpg.de/. Accessed 2014 August 27
114. Jensen M (2007-2009) PSSM. Available: http://indra.mullins.microbiol.washington.edu/webpssm/. Accessed 2014 August 27
115. Mathelier A, Zhao X, Zhang A, Parcy F, Worsley-Hunt R, et al. (2014) JASPAR 2014: an extensively expanded and updated open-access database of transcription factor binding profiles. Nucl Acids Res 42(D1): D142-D147
116. Jones E, Oliphant T, Peterson P, et al. (2001) SciPy: Open source scientific tools for Python. Available: http://www.scipy.org/. Accessed 2014 August 27